Brief: Apyx Medical Corp Announces FDA 510(K) Submission With Clinical Study Support For Use Of Renuvion APR Handpiece For Aesthetic Procedures To Improve Appearance Of Lax Skin
04/04/2022 12:09
April 4 (Reuters) - Apyx Medical Corp APYX.O :
* APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION
WITH
CLINICAL STUDY SUPPORT FOR THE USE OF THE RENUVION® APR
HANDPIECE FOR AESTHETIC PROCEDURES TO IMPROVE APPEARANCE OF LAX
SKIN
Source text for Eikon: ID:nBw8c53Tha
Further company coverage: APYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apyx Medical
See all newsBrief: Apyx Medical - Appoints Stavros Vizirgianakis As Executive Chairman Effective June 11, 2026
Brief: Apyx Medical Corporation Receives Expanded FDA 510(K) Clearance Adding Power Liposuction Capability To AYON Body Contouring System™
Apyx Medical Q1 revenue beats estimates, outlook raised
Preview: Weight-loss revolution sparks new appetite for aesthetics firms
Apyx Medical Q4 revenue beats on Surgical Aesthetics unit strength